Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Discovery Laboratories — Investor Presentation (April 2016)

31 slides from Windtree Therapeutics's investor presentation, Apr 18, 2016

  1. Slide 1: Windtree Therapeutics April 2016

    Ee we WINDTREE THERAPEUTICS" April 2016 NASDAQ: WINT

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement 2 To the extent that statements in this presentation are not strictly historical, including statements about the Company’s business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Comp

  3. Slide 3: Public biotherapeutic / medical device company

    3 Public biotherapeutic / medical device company; Nasdaq: WINT Based in Warrington, PA with 55 employees Lead program focused in the acute respiratory area

  4. Slide 4: Experienced Management Team

    4 Experienced Management Team Very experienced management team averaging over 20 years of experience developing drugs and devices and building and leading businesses

  5. Slide 5: High Value-Creating Potential

    Well characterized asset and target applicationPotential to develop a transformative therapy for an established market that has a clear unmet needBuilding a data base of potential safety, clinical effect and benefit informationOpportunity to build a positive health economic positionStrong IP with th

  6. Slide 6: AEROSURF Aerosolized Surfactant for RDS

    AEROSURF®Aerosolized Surfactant for RDS Potential to transform the treatment of premature infants with RDS by making surfactant therapy available through non-invasive delivery technology Proprietary Synthetic KL4 Surfactant Designed to be structurally similar to human lung surfactantLiquid KL4 surfa

  7. Slide 7: Respiratory Distress Syndrome (RDS)

    Primary characteristic is surfactant deficiency in underdeveloped lungs of premature infants (born with a lack of natural lung surfactant required for open airways and proper gas exchange – O2 in and CO2 out)American Academy of Pediatrics guidelines recommend providing surfactant replacement within

  8. Slide 8: Current Treatment of RDS: Intubate or Not?

    Current Treatment of RDS: Intubate or Not? Current surfactant replacement therapy (SRT) requires intubation and mechanical ventilation (MV); available surfactants are animal-derivedInvasive intubation and MV can result in serious respiratory conditions and other complications, such as higher risk of

  9. Slide 9: nCPAP Used Across All Gestational Ages and Severity of RDS

    nCPAP Used Across All Gestational Ages (GA) and Severity of RDS Frequency and Severity of RDS & Incidence of CPAP Failure Rate HIGHER LOWER GA 26-28 wks(85-95% have RDS) GA 29-32 wks(65-75% have RDS) GA 33-34 wks(40-50% have RDS) 30% ETT/SRT CPAP 70% 55% ETT/SRT CPAP 45% 70% ETT/SRT CPAP 30% Source:

  10. Slide 10: Trends in Non-Invasive Care of Neonates

    Trends in Non-Invasive Care of Neonates – Increasing Use of nCPAP to Avoid Intubation However, still experience high nCPAP failure rates First-line nCPAP use has been trending up across all gestational ages up to 32 weeks GA Est. GA: < 24 wks ~24-27 wks ~28-29 wks ~30-32 wks Source: Soll, Obstetric

  11. Slide 11: Clinicians seeking a non-invasive way to deliver SRT in RDS

    Clinicians seeking a non-invasive way to deliver SRT in RDS What is wanted1:An approach that effectively delivers surfactant without intubation or mechanical ventilationPossibility of repeat dosesAvoids clinical instability associated with bolus administrationAdministration by non-specialist staffRe

  12. Slide 12: Innovative, Proprietary Device Provides the Breakthrough

    12 Innovative, Proprietary Device Provides the Breakthrough Capillary Drug pumped through capillary Energy Input Aerosolized KL4 Surfactant via nCPAP Transformative administration of KL4 surfactant without invasive intubation and early in the management of RDS in premature infants AEROSURF®

  13. Slide 13: Bridge the Surfactant / RDS Gap in the First Hours to 72 Hours

    Bridge the Surfactant / RDS Gap in the First 72 Hours 48 to 72 Hours Surfactant Deficient Endogenous Surfactant Production Birth Provide surfactant therapy to premature infants until they can produce their own endogenous surfactantAllow for single or repeat non-invasive doses of aerosolized KL4 surf

  14. Slide 14: Comprehensive Phase 2 Program – Completed Trials

    Phase 2a Phase 2a Expansion Gestational Age (wks) 29 – 34 Dose Groups 15 min; 30 min; 45 min( 25, 50, 75 TPL mg/kg)(8 active, 8 control per group)Single dose 60 min; 90 min (100 and 150 TPL mg/kg)(8 active, 8 control per group)Primarily single dose # of patients 48 32 Objective(s) Safety and tolerab

  15. Slide 15: Phase 2a Study Objectives

    Phase 2a Study (29 to 34 wks GA)Study Objectives Primary ObjectiveSafety and tolerability of AEROSURF® compared to nCPAP aloneOther Key ObjectivesAssess physiological data indicating that aerosolized KL4 surfactant is being delivered into the lungs of premature infantsGas exchange: FiO2 requirements

  16. Slide 16: Safety and Tolerability - Summary

    Phase 2a Study (29 to 34 wks GA)Safety and Tolerability - Summary The safety and tolerability profile of AEROSURF® was generally comparable to the control groupThe Independent Safety Review Committee supports proceeding to the next studies in our programThe Aerosol Delivery System delivered KL4 surf

  17. Slide 17: Adverse Events - Incidence of Air Leak

    Phase 2a Study (29 to 34 wks GA) Adverse Events - Incidence of Air Leak Types of Air Leak Control(N=40) AEROSURF®(N=40) Pneumothorax/Pneumomediastinum 5 (13%) 9 (23%)1, 2 Pulmonary Interstitial Emphysema 2 (5%) 1 (3%) Total Number of Infants3 7 (18%) 9 (23%) 1 Includes 1 AEROSURF® patient inappropri

  18. Slide 18: Physiological Data

    Phase 2a Study (29 to 34 wks GA)Physiological Data ObjectiveEstablish proof of concept that aerosolized KL4 surfactant is being delivered into the lungs of premature infants by assessing: Need for rescue therapy and requirement for invasive respiratory support, andGas exchangeSummaryAerosolized KL4

  19. Slide 19: Time to Intubation for nCPAP Failure by Treatment Group

    Phase 2a Study (29 to 34 wks GA) Time to Intubation for nCPAP Failure by Treatment Group AEROSURF® may prolong the time to intubation; repeat dosing may be important to extend this effect to surfactant self-sufficiency Control Dose Groups 3,4 & 5 Dose Groups 1 & 2 (15 & 30 min) (45, 60 & 90 min) 19

  20. Slide 20: nCPAP Failure by Treatment Group through 72 hours

    * One intubated patient excluded due to being inappropriately enrolled 1/7* 3/8 3/8 21/40 5/8 6/8 (15 min) (30 min) (45 min) (60 min) (90 min) Phase 2a Study (29 to 34 wks GA)nCPAP Failure by Treatment Group through 72 hours AEROSURF® treatment, primarily in single doses of 45 minutes and greater, a

  21. Slide 21: 45 and 60 Minute Dose Groups - nCPAP Failure through 72 hours

    Phase 2a Study (29 to 34 wks GA) 45 and 60 Minute Dose Groups - nCPAP Failure through 72 hours Time to nCPAP Failure * One intubated patient excluded due to being inappropriately enrolled At 72 hours post-dosing, 27% of AEROSURF® patients in the combined 45 and 60 minute dose groups required intubat

  22. Slide 22: 45 and 60 Minute Dose Groups - nCPAP Failure

    Phase 2a Study (29 to 34 wks GA)45 and 60 Minute Dose Groups - nCPAP Failure through 72 hours No AEROSURF patients in the 45 and 60 minute dose groups required intubation at 3 or 6 hours post-dosing compared to 18% (7/40) of control patientsAEROSURF 45 and 60 minute doses may be reducing the rates o

  23. Slide 23: Moving Forward – Window for Repeat Dosing

    Phase 2a Study (29 to 34 wks GA)Moving Forward – Window for Repeat Dosing Potential repeat dose Additional dose if needed 45 and 60 minute Dose Groups 23 * One intubated patient excluded due to being inappropriately enrolled

  24. Slide 24: Radiographic changes post-AEROSURF in a treated patient

    Phase 2a in 29-34 week GA radiographic changes post-AEROSURF® in a treated patient* * These radiographs are illustrative of one particular patient only. They are not intended to imply that the same result can be achieved in another individual infant or group of infants or that the FDA will find AERO

  25. Slide 25: Summary - Encouraging Phase 2a Results

    Summary - Encouraging Phase 2a Results in 29 to 34 wks Gestational Age Premature Infants The goal of decreasing nCPAP failure and intubations appears achievable Aerosolized KL4 surfactant produces physiological changes that are expected with surfactant replacement therapyData to date suggest that AE

  26. Slide 26: Phase 2 Program: 2a, 2a Expansion and Phase 2b

    Phase 2a Phase 2a Expansion Phase 2a Phase 2b Gestational Age (wks) 29 – 34 26 - 28 26 – 32(Begin with 29 – 32) Dose Groups 15 min; 30 min; 45 min( 25, 50, 75 TPL mg/kg)(8 active, 8 control per group)Single dose 60 min; 90 min (100 and 150 TPL mg/kg)(8 active, 8 control per group)Primarily single do

  27. Slide 27: Large Global Revenue Opportunity

    Large Global Revenue Opportunity Regions Current Annual RevenueInvasive SRT only† Revenue Potential of AEROSURF‡ US $70 - $75 million EU $60 - $70 million LATAM $50 - $100 million ROW $50 - $100 million GLOBAL $230 - $345 million $600 million to $1.0b+ Developed World – 250k to 350k RDS PatientsOnly

  28. Slide 28: Broad Multi-Faceted Exclusivity Portfolio

    Technology Platform Exclusivities Broad Multi-Faceted Exclusivity Portfolio PatentsLyophilized KL4 Surfactant Portfolio - to 2033Aerosol Delivery System Portfolio - through 2031+Trade Secrets/Know-HowMethods of ManufactureNon-USP Analytical ProcessesPotential Regulatory ExclusivitiesMultiple Orphan

  29. Slide 29: Development Pipeline

    29 Development Pipeline The preclinical development activities listed above have been or are being funded by grants issued by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to study influenza (contract HHSN272201500027C) and radiation (aw

  30. Slide 30: Q4'15 Financial Update

    Q4’15 Financial Update Cash of $38.7M as of December 31, 2015Operating cash outflows of $7.6 million in Q4’15The Company anticipates that it has sufficient cash to fund operations through Q1’17 including the completion of the AEROSURF® phase 2b trialCurrent Liabilities and Long-term debt as of Decem

  31. Slide 31: High Value-Creating Potential

    Well characterized asset and target application in RDSPotentially transformative therapy for an established market that has a clear unmet needBuilding data base of potential safety, clinical effect and benefit informationSignificant opportunity to build a positive health economic positionStrong IP w

Discovery Laboratories — Investor Presentation (April 2016) on 6ix